Published in

Mary Ann Liebert, Human Gene Therapy, 5(26), p. 276-285, 2015

DOI: 10.1089/hum.2015.024

Links

Tools

Export citation

Search in Google Scholar

Adoptive t-cell therapy for cancer in the United Kingdom: a review of activity for the British Society of Gene and Cell Therapy Annual Meeting 2015

Journal article published in 2015 by David Edward Gilham, John Anderson, John Stephen Bridgeman, Robert Edward Hawkins, Mark Adrian Exley, Hans Stauss, John Maher, Martin Pule, Andrew Kelvin Sewell ORCID, Gavin Bendle, Steven Lee, Waseem Qasim, Adrian Thrasher, Emma Morris ORCID
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Adoptive T-cell therapy is delivering objective clinical responses across a number of cancer indications in the early phase clinical setting. Much of this clinical activity is taking place at major clinical academic centers across the United States. This review focuses upon cancer-focused cell therapy activity within the United Kingdom as a contribution to the 2015 British Society of Gene and Cell Therapy annual general meeting. This overview reflects the diversity and expansion of clinical and preclinical studies within the United Kingdom while considering the background context of this work against new infrastructural developments and the requirements of nationalized healthcare delivery within the UK National Health Service.